The US giant is accused of selling faulty hip devices to over 4,700 patients in the country and under-reporting that figure. Reportedly four deaths have happened and over 3,600 patients are untraceable. While the government is trying to identify these patients, fact is in the face of activism and a brand defeat, the company has already paid for revision surgeries and made one of the largest payouts in pharma history for those affected.
The assumption for US goodwill
That assumption that it needed the US goodwill more than the Indian one itself betrays the altruistic intent that it peddles through its many public service campaigns. In fact, it suppressed key facts of its defective implants globally, making it look like a problem of the US and containing the cascading damage in the process.
The government on its part must give up its tardy ways and while it is setting up an expert committee to monitor compensation and functioning of state committees (Maharashtra was among the first states to push for compensation in 2011 although the implant manufacture was stalled in 2010), it needs to wrestle with Johnson India that pending correctives, it would have no market in India. Already Johnson has been under siege for continuing to sell faulty baby products a few years ago.
The committee has suggested that it pay at least Rs 20 lakh to each affected patient, and the reimbursement for revision surgeries should continue until August 2025. This shouldn’t be all. All Johnson products in India should hereby be subjected to the strictest scrutiny before they get to counters. For far too long public health has been easily negotiable in India, a fact which emboldens pharma majors. The private network of hospitals too has pushed implants in return for an endorsement without keeping patients in the loop of possible consequences.